Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

East Asian Regulators Collaborate To Reduce Drug Lags (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Regulators from Japan, China, South Korea, Taiwan, Thailand and Singapore gathered in Tokyo April 14-15 at the East Asian Pharmaceutical Regulatory Symposium to discuss ways to eliminate drug approval lags in the region

You may also be interested in...



More Talks Needed With China and Japan For Cooperation In Sharing Clinical Data - Korea FDA Official

SEOUL - Although drug regulatory officials from South Korea, Japan and China met in Beijing for two days from Dec. 17 in their second tri-party meeting, they failed to report "noticeable progress" in their pursuit of an integrated clinical trial data-sharing program and mutual acceptance of their rules and guidelines, according to Korea FDA

More Talks Needed With China and Japan For Cooperation In Sharing Clinical Data - Korea FDA Official

SEOUL - Although drug regulatory officials from South Korea, Japan and China met in Beijing for two days from Dec. 17 in their second tri-party meeting, they failed to report "noticeable progress" in their pursuit of an integrated clinical trial data-sharing program and mutual acceptance of their rules and guidelines, according to Korea FDA

Japanese Regulators, With Drug Makers Support, Moves Toward East Asian Clinical Data Sharing And Acceptance

Japan is determined to further an initiative in promoting multi-regional clinical study data acceptance among East Asian countries, and the proposal has gained critical support from the nation's drug making industry

Related Content

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel